106 related articles for article (PubMed ID: 26051688)
1. Salmeterol Xinafoate.
Anwar MM; El-Haggar RS; Zaghary WA
Profiles Drug Subst Excip Relat Methodol; 2015; 40():321-69. PubMed ID: 26051688
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of salmeterol.
Cazzola M; Testi R; Matera MG
Clin Pharmacokinet; 2002; 41(1):19-30. PubMed ID: 11825095
[TBL] [Abstract][Full Text] [Related]
3. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
[TBL] [Abstract][Full Text] [Related]
4. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.
Casarosa P; Kollak I; Kiechle T; Ostermann A; Schnapp A; Kiesling R; Pieper M; Sieger P; Gantner F
J Pharmacol Exp Ther; 2011 Jun; 337(3):600-9. PubMed ID: 21357659
[TBL] [Abstract][Full Text] [Related]
5. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
[TBL] [Abstract][Full Text] [Related]
6. Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma.
Harrison LI; Novak CC; Needham MJ; Ratner P
J Aerosol Med Pulm Drug Deliv; 2011 Oct; 24(5):245-52. PubMed ID: 21671752
[TBL] [Abstract][Full Text] [Related]
7. Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma.
Akamatsu T; Shirai T; Kato M; Yasui H; Hashimoto D; Fujisawa T; Tsuchiya T; Inui N; Suda T; Chida K
Pulm Pharmacol Ther; 2014 Feb; 27(1):52-6. PubMed ID: 23583566
[TBL] [Abstract][Full Text] [Related]
8. [Combination treatment with inhaled corticosteroid/long-acting beta 2-adrenergic bronchodilator in the treatment of asthma].
Kimura T; Adachi M
Nihon Rinsho; 2001 Oct; 59(10):1992-9. PubMed ID: 11676144
[TBL] [Abstract][Full Text] [Related]
9. [Influence of changing inhalation device from separate diskus of salmeterol and fluticasone propionate to combination diskus in asthma patients].
Miyagawa T
Arerugi; 2008 Nov; 57(11):1134-44. PubMed ID: 19052508
[TBL] [Abstract][Full Text] [Related]
10. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
11. Salmeterol xinafoate in children on high dose inhaled steroids.
Russell G; Williams DA; Weller P; Price JF
Ann Allergy Asthma Immunol; 1995 Nov; 75(5):423-8. PubMed ID: 7583864
[TBL] [Abstract][Full Text] [Related]
12. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
13. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023).
Baumgarten C; Geldszus R; Behre U; Peslis N; Trautmann M;
Eur J Med Res; 2002 Jan; 7(1):1-7. PubMed ID: 11827834
[TBL] [Abstract][Full Text] [Related]
14. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group.
Simons FE
N Engl J Med; 1997 Dec; 337(23):1659-65. PubMed ID: 9385125
[TBL] [Abstract][Full Text] [Related]
15. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
[TBL] [Abstract][Full Text] [Related]
16. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice.
Tamm M; Richards DH; Beghé B; Fabbri L
Respir Med; 2012 Dec; 106 Suppl 1():S9-19. PubMed ID: 23273165
[TBL] [Abstract][Full Text] [Related]
17. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
Brogden RN; Faulds D
Allergol Immunopathol (Madr); 1992; 20(2):72-84. PubMed ID: 1359777
[TBL] [Abstract][Full Text] [Related]
18. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group.
Boyd G
Eur Respir J; 1995 Sep; 8(9):1494-8. PubMed ID: 8575574
[TBL] [Abstract][Full Text] [Related]
19. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.
Bleecker ER; Yancey SW; Baitinger LA; Edwards LD; Klotsman M; Anderson WH; Dorinsky PM
J Allergy Clin Immunol; 2006 Oct; 118(4):809-16. PubMed ID: 17030231
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma.
Wenzel SE; Lumry W; Manning M; Kalberg C; Cox F; Emmett A; Rickard K
Ann Allergy Asthma Immunol; 1998 Jun; 80(6):463-70. PubMed ID: 9647268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
